FDA accepts UGN-103 filing and UroGen Pharma stock trades at EUR 30.50

Published on 10/20/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA accepted UGN-103 on October 19, 2026. UroGen Pharma stock costs EUR 30.50 on October 20, 2026 and UGN-103 shows a 77.80 percent response rate at three months.

Regulatory review and trial evidence

FDA acceptance moved UGN-103 into review on October 19, 2026.
UTOPIA reported a 94.50 percent event-free probability at six months among responders.
UroGen Pharma stock traded at EUR 30.50 at 12:44 p.m. CEST at Lang & Schwarz on October 20, 2026.

URGN, IL0011407140, Illustration mit AI erstellt.

UroGen Pharma (ISIN IL0011407140) was trading at EUR 30.50 at Lang & Schwarz on October 20, 2026, at 12:44 p.m. CEST. On October 19, 2026, UroGen Pharma announced that the U.S. Food and Drug Administration had accepted its application for investigational bladder-cancer treatment UGN-103.

FDA review starts the next phase

The FDA assigned a Prescription Drug User Fee Act target action date of June 14, 2027. The decision gives UroGen a defined regulatory milestone for a second mitomycin-based product, while UGN-103 remains investigational and is not approved.

The application covers adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. UGN-103 uses UroGen's RTGel technology with a mitomycin formulation designed to simplify manufacturing and reconstitution, according to the October 19 release from UroGen Pharma.

What does UGN-103 mean for the pipeline?

The answer is tied to the UTOPIA trial. The study reported a 77.80 percent complete response rate at three months, while the estimated probability of remaining event-free at six months was 94.50 percent among patients who had achieved a complete response.

UTOPIA enrolled 99 patients across global sites. Participants received 75 milligrams of UGN-103 once weekly for six weeks, and responders entered follow-up lasting up to 12 months. These figures provide the clinical foundation for the FDA review rather than an approval outcome.

Three milestones since August

On August 17, 2026, UroGen submitted the NDA for UGN-103; on August 20, 2026, it announced collaboration and investment agreements with IntraGel; and on October 19, 2026, the FDA accepted the UGN-103 application. The company lists these milestones on its investor-relations site.

The next regulatory date

The next substantiated date is June 14, 2027, the FDA target action date for UGN-103. For investors, the key variable is whether the clinical response data translate into a successful regulatory decision.

Revenue gives the pipeline a commercial base

Investing.com reported second-quarter 2026 revenue of USD 72.50 million, compared with USD 24.20 million in the prior-year quarter. ZUSDURI generated USD 50.40 million in second-quarter revenue, giving the regulatory pipeline a commercial product alongside the UGN-103 development program.

Stock valuation remains event driven

UroGen Pharma had a market capitalization of USD 1.7 billion on October 19, 2026. Its 52-week range was USD 16.50 to USD 50.81 on the same date, placing the clinical decision and the next revenue update at the center of the stock's valuation.

UroGen Pharma was trading at EUR 30.50 at Lang & Schwarz on October 20, 2026, at 12:44 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of UroGen Pharma stock.